Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Breast Cancer AJCC v6 and v7 clinical trials
2 of 15 indexed Stage IV Breast Cancer AJCC v6 and v7 trials are currently recruiting.
15 US clinical trials · 2 currently recruiting
Stage IV Breast Cancer AJCC v6 and v7 is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 8 of these trials.
The research picture
Stage IV Breast Cancer AJCC v6 and v7 has 15 registered US clinical trials, 2 of them open to new participants right now, about 13% of the total.
- 2
- recruiting participants now
- 13%
- of trials open to enrollment
- 2
- in Phase 3–4 (later-stage)
- 8
- top sponsor: National Cancer Institute (NCI)
Active & Recent Trials
15 total, page 1 of 1
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
NCT03418961
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Mayo Clinic
NCT04521764
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
National Cancer Institute (NCI)
NCT02398773
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02311933
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Mayo Clinic
NCT03281902
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
National Cancer Institute (NCI)
NCT01327781
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
City of Hope Medical Center
NCT02778685
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT01251874
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
NCT01463072
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
NCT01351909
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
NCT04692103
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
NCT00785291
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
NCT01349959
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT01624441
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
City of Hope Medical Center
NCT03477396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 7 |
| Phase 3 | 2 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Stage IV Breast Cancer AJCC v6 and v7 Trial Landscape
15 indexed Stage IV Breast Cancer AJCC v6 and v7 studies · 2 recruiting (13%).
Phase mix: 2 late (III/IV) vs 12 early (I/II).
Top sponsor: National Cancer Institute (NCI) (8 trials), 4 others listed. 15 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Stage IV Breast Cancer AJCC v6 and v7?
PlainTrial tracks 15 US clinical trials for Stage IV Breast Cancer AJCC v6 and v7, of which 2 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Stage IV Breast Cancer AJCC v6 and v7?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.